Cardoso Crivaldo Gomes, Medina Fábio Leandro, Pinto Luiz Gustavo, Oneda Bruna, Costa Luiz Augusto Riani, Labes Eliana, Abrahão Sandra Baliero, Tinucci Taís, Mion Décio, Fonseca Angela Maggio, de Moraes Forjaz Cláudia Luica
From the 1Exercise Hemodynamic Laboratory, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil; 2Center for Sport and Physical Education, State University of Londrina, Londrina, Brazil; and 3Gynecology and Climacteric Service and 4Hypertension Unit, General Hospital, University of São Paulo, São Paulo, Brazil.
Menopause. 2014 Apr;21(4):376-82. doi: 10.1097/GME.0b013e31829e4a35.
The aim of this study was to evaluate the isolated and associated effects of oral estrogen therapy and aerobic training on cardiorespiratory fitness in postmenopausal women.
Forty-two hysterectomized healthy postmenopausal women were randomly divided (in a double-blind manner) into four groups: placebo-control (n = 9), estrogen therapy-control (n = 12), placebo-aerobic training (PLA-AT; n = 11), and estrogen therapy-aerobic training (ET-AT; n = 10). The estrogen therapy groups received estradiol valerate (1 mg/day) and the aerobic training groups trained on a cycle ergometer three times per week at moderate intensity. Before and 6 months after the interventions, all women underwent a maximal cardiopulmonary exercise test on a cycle ergometer.
Regardless of hormone therapy, aerobic training increased oxygen uptake at anaerobic threshold (P = 0.001), oxygen uptake at respiratory compensation point (P = 0.043), and oxygen uptake at peak exercise (P = 0.020). The increases at respiratory compensation point and peak exercise were significantly greater in the groups receiving placebo than in the groups receiving estrogen (oxygen uptake at respiratory compensation point: PLA-AT +5.3 [2.8] vs ET-AT +3.0 [2.5] mL kg(-1) min(-1), P = 0.04; oxygen uptake at peak exercise: PLA-AT +5.8 [3.4] vs ET-AT +2.8 [1.4] mL kg(-1) min(-1), P = 0.02).
Oral estrogen therapy may mitigate the cardiorespiratory fitness increase induced by aerobic training in hysterectomized healthy postmenopausal women.
本研究旨在评估口服雌激素疗法和有氧运动训练对绝经后女性心肺适能的单独及联合影响。
42名接受子宫切除的健康绝经后女性被随机（双盲方式）分为四组：安慰剂对照组（n = 9）、雌激素疗法对照组（n = 12）、安慰剂-有氧运动训练组（PLA-AT；n = 11）和雌激素疗法-有氧运动训练组（ET-AT；n = 10）。雌激素疗法组接受戊酸雌二醇（1毫克/天），有氧运动训练组每周在功率自行车上进行三次中等强度训练。在干预前和干预6个月后，所有女性均在功率自行车上进行了最大心肺运动测试。
无论激素疗法如何，有氧运动训练均增加了无氧阈时的摄氧量（P = 0.001）、呼吸补偿点时的摄氧量（P = 0.043）和运动峰值时的摄氧量（P = 0.020）。接受安慰剂的组在呼吸补偿点和运动峰值时的增加量显著大于接受雌激素的组（呼吸补偿点时的摄氧量：PLA-AT +5.3 [2.8] 对比ET-AT +
3.0 [2.5] 毫升·千克⁻¹·分钟⁻¹, P = 0.04；运动峰值时的摄氧量：PLA-AT +5.8 [3.4] 对比ET-AT + 2.8 [1.4] 毫升·千克⁻¹·分钟⁻¹, P = 0.02）。
口服雌激素疗法可能会减轻子宫切除的健康绝经后女性因有氧运动训练而导致的心肺适能增加。
